Tadiran forecasts Q4 loss

Defense company Tadiran Communications said it expects a fourth-quarter loss of between $10 million and $15m. following a seven-week strike at its Holon plant that ended last week.

By YIGAL GRAYEFF
January 5, 2006 06:49

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Defense company Tadiran Communications said it expects a fourth-quarter loss of between $10 million and $15m. following a seven-week strike at its Holon plant that ended last week. The company said on Wednesday the strike forced it to delay completion of sales worth about $20m., but that the factory has now returned to full production. The company has a backlog of $350m. Tadiran also said it signed a collective agreement with the Histadrut labor federation that will lead to 50 workers taking early retirement.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS